Semaglutide (Ozempic) vs Semaglutide (Rybelsus)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)

Result source: NCT03819153

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT06050577 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSemaglutide (Ozempic)Semaglutide (Rybelsus)
HbA1c, change-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082
Body weight, change (kg)-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082
HbA1c below 7%72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
—Not posted · NCT04596631, expected 2026-08
Fasting plasma glucose, change-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
3-point MACE (% with event)6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result

HbA1c, change

Semaglutide (Ozempic)
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
Semaglutide (Rybelsus)
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082

Body weight, change (kg)

Semaglutide (Ozempic)
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
Semaglutide (Rybelsus)
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082

HbA1c below 7%

Semaglutide (Ozempic)
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
Semaglutide (Rybelsus)
—Not posted · NCT04596631, expected 2026-08

Fasting plasma glucose, change

Semaglutide (Ozempic)
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
Semaglutide (Rybelsus)
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080

3-point MACE (% with event)

Semaglutide (Ozempic)
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
Semaglutide (Rybelsus)
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
41 other shared endpoints and safety

Coverage. Semaglutide (Ozempic): 45 of 45 rows · Semaglutide (Rybelsus): 44 of 45 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Ozempic)
Rows use multiple source trials
Semaglutide (Rybelsus)
Rows use multiple source trials
BMI
absolute change · kg
-1.5 vs 1 Insulin Aspart kg @ 52wka,b
NCT03689374 · Phase 3 · registry result, not featured evidence
1 other source trial
-2 vs -1.5 Canagliflozin kg @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
-1.5 vs -1.4 Empagliflozin 25 mg kg @ 52wk14 mga,b
NCT02863328 · Phase 3
14 other source trials
-1.2 vs -0.3 Sitagliptin kg @ 52wk14 mg
NCT02607865 · Phase 3
-0.6 vs -0.3 Sitagliptin kg @ 52wk3 mg
NCT02607865 · Phase 3
-0.9 vs -0.3 Sitagliptin kg @ 52wk7 mg
NCT02607865 · Phase 3
-1.6 vs -0.4 placebo kg @ 52wk14 mg
NCT02863419 · Phase 3
-1.4 vs 0.2 placebo kg @ 52wk14 mg
NCT03021187 · Phase 3
-0.3 vs 0.2 placebo kg @ 52wk3 mg
NCT03021187 · Phase 3
-0.8 vs 0.2 placebo kg @ 52wk7 mg
NCT03021187 · Phase 3
-1 vs -0.3 Sitagliptin kg @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.4 placebo kg @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0 vs -0.4 placebo kg @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.4 placebo kg @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.6 vs 0.3 Dulaglutide kg @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0 vs 0.3 Dulaglutide kg @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.3 vs 0.3 Dulaglutide kg @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
BMI
absolute change · kg
No placebo or comparator arm
-2.5 kg @ 40wk2.0 mg weeklyc,a,b,d
NCT03989232 · Phase 3
show 1 more dose
-2.1 kg @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
-1.3 kg @ 104wka,b,d
NCT02849080 · Phase 3 · registry result, not featured evidence
DBP
absolute change · mmHg
-0.4 vs -0.8 placebo mmHg @ 104wke,b,f
NCT03819153 · Phase 3
1 other source trial
-1.9 vs -1.4 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-2 vs -2 placebo mmHg @ 26wk14 mgc,e,b,f
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1 vs -2 placebo mmHg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0 vs -2 placebo mmHg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-1.29 mmol/L @ 52wka,b
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-1.41 mmol/L @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-2.4 mmol/L @ 52wk14 mg once dailyc,a,b
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
-3.2 mmol/L @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-3 mmol/L @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
On-treatment without rescue medication
-1.7% (n=394) vs -1% (n=394) Canagliflozin @ 52wka,b,g
On-treatment without rescue medication
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
-1.7% (n=48) vs -0.2% (n=49) placebo @ 26wk14 mgc,a,b,g
NCT03018028 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1.7% (n=49) vs -0.2% (n=49) placebo @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.1% (n=49) vs -0.2% (n=49) placebo @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.23% (n=91) @ 52wka,b
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-0.86% (n=335) @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.5% (n=497) @ 52wk14 mg once dailyc,a,b
NCT04707469 · Phase 3 · registry result, not featured evidence
show 5 more doses
-0.4% (n=333) @ 52wk14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-2.1% (n=492) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-1% (n=339) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-1.9% (n=475) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-0.8% (n=345) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c 6.5 or Less
event count · % of participants
47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk*1.0 mga,b,h
Yes
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted
63.8% (n=160) vs 17.9% (n=168) placebo @ 26wk*14 mgc,a,b,h
NCT02906930 · Phase 3 · converted to % from 102 Participants as posted
show 2 more doses
47.5% (n=160) vs 17.9% (n=168) placebo @ 26wk*7 mg
NCT02906930 · Phase 3 · converted to % from 76 Participants as posted
35.9% (n=167) vs 17.9% (n=168) placebo @ 26wk*3 mg
NCT02906930 · Phase 3 · converted to % from 60 Participants as posted
HbA1c 7.0 or Less
event count · % of participants
81.6% (n=288) vs 28.7% (n=94) placebo @ 72wk*7.2 mgi,j,e,b,k
NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 235 Participants as posted
91.3% (n=46) vs 35.3% (n=51) placebo @ 26wk*40 mgc,i,j,e,b,k
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 42 Participants as posted
show 6 more doses
86.4% (n=44) vs 35.3% (n=51) placebo @ 26wk*40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
90.4% (n=52) vs 35.3% (n=51) placebo @ 26wk*40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 47 Participants as posted
85.4% (n=48) vs 35.3% (n=51) placebo @ 26wk*20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 41 Participants as posted
86% (n=57) vs 35.3% (n=51) placebo @ 26wk*10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 49 Participants as posted
86.2% (n=58) vs 35.3% (n=51) placebo @ 26wk*5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 50 Participants as posted
48.2% (n=56) vs 35.3% (n=51) placebo @ 26wk*2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
HbA1c Less Than 7 or Reduction Ge 1
event count · % of participants
74.7% (n=430) vs 65.2% (n=462) Standard of Care @ 52wk*a,b
Yes
NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 321 Participants as posted
73.3% (n=326) vs 61.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*a,b
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 239 Participants as posted
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
event count · % of participants
48.5% (n=410) vs 37.3% (n=426) Standard of Care @ 52wk*l,a,b
Yes
NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 199 Participants as posted
45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*l,a,b
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted
HbA1c Less Than 7%
event count · % of participants
56.7% (n=430) vs 48.9% (n=462) Standard of Care @ 52wk*a,b
Yes
NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 244 Participants as posted
58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*a,b
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
67.6% (n=480) @ 40wk2.0 mg weeklyc,a,b,m
NCT03989232 · Phase 3
show 1 more dose
57.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
39.2% (n=536) @ 68wk14 mg once dailyc,a,b,m
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
58.9% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
49.9% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
event count · % of participants
No placebo or comparator arm
56.5% (n=92) @ 24wk*l,a,b,n
Yes
NCT05533632 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted
56.1% (n=180) @ 104wk*l,a,b,n
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 101 Participants as posted
HbA1c Less Than or Equal to 6.5
event count · % of participants
72.6% (n=288) vs 16% (n=94) placebo @ 72wk*7.2 mgi,o,e,b,p
NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 209 Participants as posted
39% (n=326) vs 23.2% (n=293) Other Oral Glucose-lowering Medication @ 52wk*i,o,e,b,p
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 127 Participants as posted
1 other source trial
33% (n=230) vs 12.2% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 76 Participants as posted
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
No placebo or comparator arm
51.7% (n=480) @ 40wk2.0 mg weeklyc,a,b,m
NCT03989232 · Phase 3
show 1 more dose
38.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
23.6% (n=536) @ 68wk14 mg once dailyc,a,b,m
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
46.2% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
35.8% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c Target Attainment
event count · % of participants
50.2% (n=430) vs 36.8% (n=462) Standard of Care @ 52wk*a,b
Yes
NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 216 Participants as posted
68.1% (n=326) vs 58.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*c,a,b
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 222 Participants as posted
show 1 more dose
54.9% (n=326) vs 40.3% (n=293) Other Oral Glucose-lowering Medication @ 52wk*
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 179 Participants as posted
HDL Cholesterol
ratio to baseline · ratio
1.04 vs 0.99 placebo ratio @ 52wke,b
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
1 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
1.04 vs 1.08 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.01 vs 1.06 Empagliflozin 25 mg ratio @ 52wk14 mge,b
NCT02863328 · Phase 3
15 other source trials
1.01 vs 0.99 Sitagliptin ratio @ 52wk14 mg
NCT02607865 · Phase 3
0.99 vs 0.99 Sitagliptin ratio @ 52wk3 mg
NCT02607865 · Phase 3
1.01 vs 0.99 Sitagliptin ratio @ 52wk7 mg
NCT02607865 · Phase 3
1.03 vs 1 placebo ratio @ 52wk14 mg
NCT02863419 · Phase 3
1.01 vs 1 placebo ratio @ 52wk14 mg
NCT03021187 · Phase 3
1.01 vs 1 placebo ratio @ 52wk3 mg
NCT03021187 · Phase 3
0.98 vs 1 placebo ratio @ 52wk7 mg
NCT03021187 · Phase 3
1.05 vs 1.02 placebo ratio
NCT02692716 · Phase 3
1 vs 1.02 Sitagliptin ratio @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
0.99 vs 1.04 placebo ratio @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
1.05 vs 1.04 placebo ratio @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
1.01 vs 1.04 placebo ratio @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
1.01 vs 1 Dulaglutide ratio @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.03 vs 1 Dulaglutide ratio @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.99 vs 1 Dulaglutide ratio @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Hypoglycemia Episodes Level 3
event count · count
6 vs 14 Insuline Glargine U100 (Titrated) count @ 40wke,b,q
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
88 vs 121 placebo count @ 265wke,b,q
NCT03914326 · Phase 3
LDL Cholesterol
ratio to baseline · ratio
0.99 vs 1.03 placebo ratio @ 52wke,b
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
1 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
0.96 vs 1.05 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
0.97 vs 1.03 Empagliflozin 25 mg ratio @ 52wk14 mge,b
NCT02863328 · Phase 3
15 other source trials
0.99 vs 1.03 Sitagliptin ratio @ 52wk14 mg
NCT02607865 · Phase 3
1.02 vs 1.03 Sitagliptin ratio @ 52wk3 mg
NCT02607865 · Phase 3
0.99 vs 1.03 Sitagliptin ratio @ 52wk7 mg
NCT02607865 · Phase 3
0.99 vs 1.06 placebo ratio @ 52wk14 mg
NCT02863419 · Phase 3
0.95 vs 1 placebo ratio @ 52wk14 mg
NCT03021187 · Phase 3
0.97 vs 1 placebo ratio @ 52wk3 mg
NCT03021187 · Phase 3
0.96 vs 1 placebo ratio @ 52wk7 mg
NCT03021187 · Phase 3
0.96 vs 0.97 placebo ratio
NCT02692716 · Phase 3
0.97 vs 1.03 Sitagliptin ratio @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
0.91 vs 1.06 placebo ratio @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.99 vs 1.06 placebo ratio @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.96 vs 1.06 placebo ratio @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.92 vs 0.91 Dulaglutide ratio @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.98 vs 0.91 Dulaglutide ratio @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.94 vs 0.91 Dulaglutide ratio @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
MALE
event rate · % of participants
0.9% (n=1767) vs 1.6% (n=1766) placebo*e,b,r
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
1.5% (n=4825) vs 2.1% (n=4825) placebo @ 265wk*e,b,r
NCT03914326 · Phase 3 · converted to % from 71 Participants as posted
Non-fatal MI
event count · % of participants
2.9% (n=1767) vs 3.6% (n=1766) placebo*e,b,r
NCT03819153 · Phase 3 · converted to % from 52 Participants as posted
4% (n=4825) vs 5.2% (n=4825) placebo @ 265wk*e,b,r
NCT03914326 · Phase 3 · converted to % from 191 Participants as posted
PPG Excursion
absolute change · mmol/L
-0.7 vs -0.9 Insulin Aspart mmol/L @ 52wka,b
NCT03689374 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.4 Empagliflozin 25 mg mmol/L @ 52wk14 mga,b
NCT02863328 · Phase 3
13 other source trials
-0.7 vs -0.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-0.5 vs -0.4 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-0.3 vs -0.3 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-2 vs -0.1 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.1 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.1 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.7 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.7 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.7 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Renal Death
event count · % of participants
0.3% (n=1767) vs 0.3% (n=1766) placebo*e,b,r
NCT03819153 · Phase 3 · converted to % from 5 Participants as posted
0% (n=4825) vs 0.1% (n=4825) placebo @ 265wk*e,b,r
NCT03914326 · Phase 3 · converted to % from 1 Participants as posted
SBP
absolute change · mmHg
-3.9 vs -1.4 placebo mmHg @ 104wke,b,f
NCT03819153 · Phase 3
1 other source trial
-3 vs -2.8 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-4 vs -2 placebo mmHg @ 26wk14 mgc,e,b,f
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2 vs -2 placebo mmHg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1 vs -2 placebo mmHg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
SF-36 Bodily Pain
absolute change · score
Bodily pain
1.54 vs 1.69 Dulaglutide score @ 40wk1.0 mgc,a,b,s
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.96 vs 1.69 Dulaglutide score @ 40wk0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0.51 vs 0.22 Sitagliptin score @ 26wk14 mgc,a,b,s
NCT04017832 · Phase 3 · registry result, not featured evidence
show 2 more doses
-0.37 vs 0.22 Sitagliptin score @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.06 vs 0.22 Sitagliptin score @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
SF-36 General Health
absolute change · score
General health
2.52 vs 1.86 Dulaglutide score @ 40wk1.0 mgc,a,b,s
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
2.65 vs 1.86 Dulaglutide score @ 40wk0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
1.95 vs 0.95 Sitagliptin score @ 26wk14 mgc,a,b,s
NCT04017832 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.04 vs 0.95 Sitagliptin score @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1.47 vs 0.95 Sitagliptin score @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
SF-36 Vitality
absolute change · score
Vitality
1.97 vs 2.14 Dulaglutide score @ 40wk1.0 mgc,a,b,s
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
1.23 vs 2.14 Dulaglutide score @ 40wk0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
1.21 vs 0.33 Sitagliptin score @ 26wk14 mgc,a,b,s
NCT04017832 · Phase 3 · registry result, not featured evidence
show 2 more doses
0.84 vs 0.33 Sitagliptin score @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.44 vs 0.33 Sitagliptin score @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
SMBG 7-point
absolute change · mmol/L
-2.1 vs -2.1 Insulin Aspart mmol/L @ 52wka,b
NCT03689374 · Phase 3 · registry result, not featured evidence
1 other source trial
-2.8 vs -1.9 Canagliflozin mmol/L @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
-2.3 vs -2.1 Empagliflozin 25 mg mmol/L @ 52wk14 mga,b
NCT02863328 · Phase 3
13 other source trials
-1.8 vs -1.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-1.3 vs -1.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-1.5 vs -1.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-2.2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-1.6 vs -0.9 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-1.7 vs -0.9 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-3.1 vs 0 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.7 vs 0 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.2 vs 0 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.7 vs -2.6 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.6 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Total Cholesterol
ratio to baseline · ratio
0.96 vs 1 placebo ratio @ 52wke,b
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
1 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
0.96 vs 1.03 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
0.97 vs 1.01 Empagliflozin 25 mg ratio @ 52wk14 mge,b
NCT02863328 · Phase 3
15 other source trials
0.98 vs 1.01 Sitagliptin ratio @ 52wk14 mg
NCT02607865 · Phase 3
1 vs 1.01 Sitagliptin ratio @ 52wk3 mg
NCT02607865 · Phase 3
0.99 vs 1.01 Sitagliptin ratio @ 52wk7 mg
NCT02607865 · Phase 3
0.98 vs 1.02 placebo ratio @ 52wk14 mg
NCT02863419 · Phase 3
0.95 vs 1 placebo ratio @ 52wk14 mg
NCT03021187 · Phase 3
0.98 vs 1 placebo ratio @ 52wk3 mg
NCT03021187 · Phase 3
0.97 vs 1 placebo ratio @ 52wk7 mg
NCT03021187 · Phase 3
0.97 vs 0.98 placebo ratio
NCT02692716 · Phase 3
0.96 vs 1.01 Sitagliptin ratio @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
0.93 vs 1.01 placebo ratio @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.99 vs 1.01 placebo ratio @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.95 vs 1.01 placebo ratio @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.94 vs 0.93 Dulaglutide ratio @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.98 vs 0.93 Dulaglutide ratio @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.95 vs 0.93 Dulaglutide ratio @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Triglyceride
ratio to baseline · ratio
0.8 vs 0.95 placebo ratio @ 52wke,b
NCT04560998 · Phase 3 · registry result, not featured evidence
2 other source trials
0.9 vs 1 Insulin Aspart ratio @ 52wk
NCT03689374 · Phase 3 · registry result, not featured evidence
0.86 vs 0.92 Canagliflozin ratio @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
0.89 vs 0.9 Empagliflozin 25 mg ratio @ 52wk14 mge,b
NCT02863328 · Phase 3
15 other source trials
0.93 vs 0.98 Sitagliptin ratio @ 52wk14 mg
NCT02607865 · Phase 3
1 vs 0.98 Sitagliptin ratio @ 52wk3 mg
NCT02607865 · Phase 3
0.97 vs 0.98 Sitagliptin ratio @ 52wk7 mg
NCT02607865 · Phase 3
0.87 vs 0.97 placebo ratio @ 52wk14 mg
NCT02863419 · Phase 3
0.86 vs 0.97 placebo ratio @ 52wk14 mg
NCT03021187 · Phase 3
0.93 vs 0.97 placebo ratio @ 52wk3 mg
NCT03021187 · Phase 3
0.94 vs 0.97 placebo ratio @ 52wk7 mg
NCT03021187 · Phase 3
0.92 vs 0.97 placebo ratio
NCT02692716 · Phase 3
0.89 vs 0.91 Sitagliptin ratio @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
0.86 vs 0.82 placebo ratio @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.86 vs 0.82 placebo ratio @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.84 vs 0.82 placebo ratio @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.87 vs 0.88 Dulaglutide ratio @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.89 vs 0.88 Dulaglutide ratio @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.87 vs 0.88 Dulaglutide ratio @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
UACR
ratio to baseline · ratio
0.6 vs 0.89 placebo ratio @ 104wke,b,f
NCT03819153 · Phase 3
0.86 vs 1.19 placebo ratio @ 26wk14 mge,b,f
NCT02827708 · Phase 3
VLDL Cholesterol
ratio to baseline · ratio
0.95 vs 0.86 placebo ratio @ 34wk21.6 mgc,t,a,u
NCT05144984 · Phase 2 · registry result, not featured evidence
show 4 more doses
0.72 vs 0.86 placebo ratio @ 34wk2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.75 vs 0.86 placebo ratio @ 34wk2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.78 vs 0.86 placebo ratio @ 34wk2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.76 vs 0.86 placebo ratio @ 34wk2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
0.91 vs 0.94 Sitagliptin ratio @ 78wk14 mgc,t,a,u
NCT02607865 · Phase 3
show 2 more doses
0.94 vs 0.94 Sitagliptin ratio @ 78wk7 mg
NCT02607865 · Phase 3
0.95 vs 0.94 Sitagliptin ratio @ 78wk3 mg
NCT02607865 · Phase 3
Waist Circumference Change
absolute change · cm
-3.3 vs 2.1 Insulin Aspart cm @ 52wka,b
NCT03689374 · Phase 3 · registry result, not featured evidence
1 other source trial
-4.2 vs -3 Canagliflozin cm @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
-3.7 vs -2.9 Empagliflozin 25 mg cm @ 52wk14 mga,b
NCT02863328 · Phase 3
14 other source trials
-2.6 vs -0.5 Sitagliptin cm @ 52wk14 mg
NCT02607865 · Phase 3
-1.3 vs -0.5 Sitagliptin cm @ 52wk3 mg
NCT02607865 · Phase 3
-2.3 vs -0.5 Sitagliptin cm @ 52wk7 mg
NCT02607865 · Phase 3
-4.4 vs -1.7 placebo cm @ 52wk14 mg
NCT02863419 · Phase 3
-4 vs 0.3 placebo cm @ 52wk14 mg
NCT03021187 · Phase 3
-0.8 vs 0.3 placebo cm @ 52wk3 mg
NCT03021187 · Phase 3
-2.3 vs 0.3 placebo cm @ 52wk7 mg
NCT03021187 · Phase 3
-2.6 vs -0.7 Sitagliptin cm @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-2.7 vs -0.9 placebo cm @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.2 vs -0.9 placebo cm @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1 vs -0.9 placebo cm @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.7 vs 0.7 Dulaglutide cm @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.1 vs 0.7 Dulaglutide cm @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs 0.7 Dulaglutide cm @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Waist Circumference Change
absolute change · cm
No placebo or comparator arm
-5.9 cm @ 40wk2.0 mg weeklyc,a,b,d
NCT03989232 · Phase 3
show 1 more dose
-5.2 cm @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
-2.5 cm @ 104wka,b,d
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight
percent change · % of baseline
-4.47% (n=389) vs -2.68% (n=386) Standard of Care @ 104wkl,a,b
NCT03596450 · Phase 4 · registry result, not featured evidence
-3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wkl,a,b
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-3.85 kg @ 52wka,b
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-3.77 kg @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-4.4 kg @ 52wk14 mg once dailyc,a,b
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
-8.3 kg @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-7.1 kg @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Weight Loss 10%
event count · % of participants
62.9% (n=291) vs 11.6% (n=95) placebo @ 72wk*7.2 mge,b,p
Yes
NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 183 Participants as posted
6.4% (n=233) vs 2.1% (n=239) Sitagliptin @ 52wk*e,b,p
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
Weight Loss 10%
responder rate · % of participants
No placebo or comparator arm
28.4% (n=480) @ 40wk2.0 mg weeklyc,a,b,m
NCT03989232 · Phase 3
show 1 more dose
22.6% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
14.3% (n=536) @ 68wk14 mg once dailyc,a,b,m
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
34.7% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
29.4% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Weight Loss 5%
event count · % of participants
86.3% (n=291) vs 34.7% (n=95) placebo @ 72wk*7.2 mgo,e,b,p
Yes
NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 251 Participants as posted
36.9% (n=298) vs 31.9% (n=260) Other Oral Glucose-lowering Medication @ 52wk*o,e,b,p
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted
1 other source trial
27% (n=233) vs 12.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 63 Participants as posted
Weight Loss 5%
responder rate · % of participants
No placebo or comparator arm
59.2% (n=480) @ 40wk2.0 mg weeklyc,a,b,m
NCT03989232 · Phase 3
show 1 more dose
51.3% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
42.2% (n=536) @ 68wk14 mg once dailyc,a,b,m
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
65.7% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
58.5% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Weight Loss 5%
event count · % of participants
No placebo or comparator arm
60.9% (n=92) @ 24wk*l,a,b,n
Yes
NCT05533632 · Phase 4 · registry result, not featured evidence · converted to % from 56 Participants as posted
33.9% (n=180) @ 104wk*l,a,b,n
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 61 Participants as posted
Dropout rate
1.3%1.0 mgv
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
1.7%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.4%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
7.8%0.5 mg weekly
NCT02054897 · Phase 3
5.1%1.0 mg weekly
NCT01930188 · Phase 3 · combination
5.4%0.5 mg weekly
NCT01930188 · Phase 3 · combination
5.3%1.0 mg/week
NCT02128932 · Phase 3
7.5%0.5 mg/week
NCT02128932 · Phase 3
3.8%2.0 mg weekly
NCT03989232 · Phase 3
2.1%1.0 mg weekly
NCT03989232 · Phase 3
3.8%1.0 mg weekly
NCT02305381 · Phase 3
3.8%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
10.6%
NCT05533632 · Phase 4 · registry result, not featured evidence
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
28.1%
NCT03596450 · Phase 4 · registry result, not featured evidence
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
1.7%Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
3.9%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
18.3%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
7.6%
NCT04560998 · Phase 3 · registry result, not featured evidence
1.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
9.7%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
8.7%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.9%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
2.6%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7.3%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
4.1%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.5%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.9%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
8.2%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
11.3%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
12.9%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
3.9%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.7%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.9%14 mgw
NCT02906930 · Phase 3
show 39 more results
8%7 mg
NCT02906930 · Phase 3
3.4%3 mg
NCT02906930 · Phase 3
2.7%14 mg
NCT02863328 · Phase 3
5.8%14 mg
NCT02607865 · Phase 3
6.4%7 mg
NCT02607865 · Phase 3
7.1%3 mg
NCT02607865 · Phase 3
2.8%14 mg
NCT02863419 · Phase 3
3.1%14 mg
NCT02827708 · Phase 3
3.3%14 mg
NCT03021187 · Phase 3
4.9%7 mg
NCT03021187 · Phase 3
5.4%3 mg
NCT03021187 · Phase 3
1.5%
NCT03914326 · Phase 3
0.3%
NCT02692716 · Phase 3
11.8%
NCT05035082 · Phase 4 · registry result, not featured evidence
5.4%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
5.6%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.4%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
7.2%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
5%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.6%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
2.1%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
2.3%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.5%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
2.3%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
11.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
11.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
5.7%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
8.6%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—1.0 mgv
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
—0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT03819153 · Phase 3
—1.0 mg weekly
NCT02054897 · Phase 3
—0.5 mg weekly
NCT02054897 · Phase 3
—1.0 mg weekly
NCT01930188 · Phase 3 · combination
—0.5 mg weekly
NCT01930188 · Phase 3 · combination
—1.0 mg/week
NCT02128932 · Phase 3
—0.5 mg/week
NCT02128932 · Phase 3
—2.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT02305381 · Phase 3
—0.5 mg weekly
NCT02305381 · Phase 3
—
NCT04126603 · Phase 4 · registry result, not featured evidence
—
NCT05786521 · Phase 4 · registry result, not featured evidence
3.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
2.2%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
—
NCT04560998 · Phase 3 · registry result, not featured evidence
—
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
—1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
0%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
—2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—14 mgw
NCT02906930 · Phase 3
show 39 more results
—7 mg
NCT02906930 · Phase 3
—3 mg
NCT02906930 · Phase 3
—14 mg
NCT02863328 · Phase 3
—14 mg
NCT02607865 · Phase 3
—7 mg
NCT02607865 · Phase 3
—3 mg
NCT02607865 · Phase 3
—14 mg
NCT02863419 · Phase 3
—14 mg
NCT02827708 · Phase 3
—14 mg
NCT03021187 · Phase 3
—7 mg
NCT03021187 · Phase 3
—3 mg
NCT03021187 · Phase 3
—
NCT03914326 · Phase 3
—
NCT02692716 · Phase 3
—
NCT05035082 · Phase 4 · registry result, not featured evidence
—14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Serious AEs
33.6%1.0 mgv
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
35%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
9.4%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
49.6%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
5.5%0.5 mg weekly
NCT02054897 · Phase 3
7.3%1.0 mg weekly
NCT01930188 · Phase 3 · combination
7.3%0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.7%1.0 mg/week
NCT02128932 · Phase 3
6.1%0.5 mg/week
NCT02128932 · Phase 3
4.4%2.0 mg weekly
NCT03989232 · Phase 3
5.2%1.0 mg weekly
NCT03989232 · Phase 3
9.2%1.0 mg weekly
NCT02305381 · Phase 3
6.1%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
1%
NCT05533632 · Phase 4 · registry result, not featured evidence
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
6%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
5.9%INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
9.8%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
19.7%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
18.7%
NCT04560998 · Phase 3 · registry result, not featured evidence
6.2%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
7.4%
NCT03689374 · Phase 3 · registry result, not featured evidence
6.6%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.3%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
4.6%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
5.9%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
4.7%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7.7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5.6%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
7.9%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
5.8%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
6.7%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
1.6%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.3%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
2.6%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
7.8%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.5%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
4.1%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
1.1%14 mgw
NCT02906930 · Phase 3
show 39 more results
1.7%7 mg
NCT02906930 · Phase 3
2.9%3 mg
NCT02906930 · Phase 3
6.6%14 mg
NCT02863328 · Phase 3
9.5%14 mg
NCT02607865 · Phase 3
10.1%7 mg
NCT02607865 · Phase 3
13.7%3 mg
NCT02607865 · Phase 3
10.9%14 mg
NCT02863419 · Phase 3
10.4%14 mg
NCT02827708 · Phase 3
6.6%14 mg
NCT03021187 · Phase 3
10.5%7 mg
NCT03021187 · Phase 3
13.6%3 mg
NCT03021187 · Phase 3
47.9%
NCT03914326 · Phase 3
18.9%
NCT02692716 · Phase 3
10.2%
NCT05035082 · Phase 4 · registry result, not featured evidence
9.9%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.2%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
10.7%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
3%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.9%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
7.7%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
4.6%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
9.5%Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
14.2%Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
9%Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
0%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
4.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
5.4%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
3%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
6.9%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
1.4%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1.0 mgv
nausea 21.8% (placebo 7.5%)
diarrhoea 18% (placebo 11.8%)
vomiting 14.8% (placebo 5.1%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 42 more results
0.5 mg
diarrhoea 17.9% (placebo 11.8%)
nausea 17.3% (placebo 7.5%)
lipase increased 11.4% (placebo 8%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
1.0 mg
nausea 22.3%
diarrhoea 11.4%
lipase increased 10.1%
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
diabetic retinopathy 19.2% (placebo 18.4%)
covid-19 12.5% (placebo 13.9%)
NCT03819153 · Phase 3
1.0 mg weekly
nausea 23.8% (placebo 7.8%)
diarrhoea 10.8% (placebo 2.3%)
headache 6.9% (placebo 6.2%)
NCT02054897 · Phase 3
0.5 mg weekly
nausea 20.3% (placebo 7.8%)
diarrhoea 12.5% (placebo 2.3%)
headache 11.7% (placebo 6.2%)
NCT02054897 · Phase 3
1.0 mg weekly
nausea 17.6%
diarrhoea 13%
vomiting 10%
NCT01930188 · Phase 3 · combination
0.5 mg weekly
nausea 17.8%
diarrhoea 13%
nasopharyngitis 12.2%
NCT01930188 · Phase 3 · combination
1.0 mg/week
nausea 22.2%
diarrhoea 19.2%
vomiting 10.3%
NCT02128932 · Phase 3
0.5 mg/week
nausea 21.3%
diarrhoea 16.3%
nasopharyngitis 12.4%
NCT02128932 · Phase 3
2.0 mg weekly
nausea 14.4%
diarrhoea 9.4%
vomiting 7.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 14.6%
diarrhoea 8.8%
vomiting 6.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 16.8% (placebo 4.5%)
vomiting 11.5% (placebo 3%)
diarrhoea 6.9% (placebo 1.5%)
NCT02305381 · Phase 3
0.5 mg weekly
nausea 11.4% (placebo 4.5%)
lipase increased 9.1% (placebo 3%)
nasopharyngitis 8.3% (placebo 10.5%)
NCT02305381 · Phase 3
abdominal pain 60%
NCT05786521 · Phase 4 · registry result, not featured evidence
nausea 11.5%
diarrhea 5.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nausea 18.4%
diarrhoea 13.5%
vomiting 9.7%
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
7.2 mg
nausea 29% (placebo 11.8%)
diarrhoea 18.2% (placebo 8.8%)
vomiting 16.6% (placebo 2.9%)
NCT05649137 · Phase 3 · registry result, not featured evidence
1.0 mg
covid-19 5.6% (placebo 0%)
decreased appetite 5.6% (placebo 0%)
diabetic retinopathy 5.6% (placebo 5.7%)
NCT04865770 · Phase 3 · registry result, not featured evidence
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3 · registry result, not featured evidence
covid-19 14.4%
diarrhoea 12.1%
nausea 11.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 14.8%
diarrhoea 7.4%
nasopharyngitis 6.5%
NCT03689374 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
diarrhoea 16.9%
nausea 13.4%
upper respiratory tract infection 13.1%
NCT03061214 · Phase 3 · registry result, not featured evidence
0.5 mg weekly
diarrhoea 20.2%
upper respiratory tract infection 9.8%
lipase increased 7.7%
NCT03061214 · Phase 3 · registry result, not featured evidence
nausea 22.7%
diarrhoea 15.1%
vomiting 12.8%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.0 mg
nausea 21.5%
diarrhoea 15.6%
decreased appetite 10.4%
NCT03191396 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
nausea 19.3% (placebo 3.3%)
diarrhoea 11.3% (placebo 6%)
vomiting 9.3% (placebo 2%)
NCT03086330 · Phase 3 · registry result, not featured evidence
1.0 mg
nausea 21%
diarrhoea 13.7%
vomiting 10.3%
NCT02648204 · Phase 3 · registry result, not featured evidence
0.5 mg
nausea 22.3%
diarrhoea 14.3%
vomiting 10%
NCT02648204 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 31.1%
nausea 19.1%
diarrhoea 15.8%
NCT02207374 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 33.9%
constipation 18.4%
nausea 12.1%
NCT02207374 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 17.6%
nausea 12.7%
constipation 11.8%
NCT02254291 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16.5%
constipation 14.6%
nausea 10.7%
NCT02254291 · Phase 3 · registry result, not featured evidence
2.0 mg
nausea 21.7% (placebo 15.3%)
vomiting 18.3% (placebo 6.8%)
diarrhoea 15% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
16.0 mg
nausea 37.1% (placebo 15.3%)
vomiting 25.8% (placebo 6.8%)
diarrhoea 21% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
8.0 mg
nausea 41.7% (placebo 15.3%)
diarrhoea 33.3% (placebo 11.9%)
vomiting 23.3% (placebo 6.8%)
NCT05486065 · Phase 2 · registry result, not featured evidence
21.6 mg
injection site erythema 10.2% (placebo 0%)
injection site reaction 10.2% (placebo 0%)
diarrhoea 8.5% (placebo 11.5%)
NCT05144984 · Phase 2 · registry result, not featured evidence
2.4 mg + 12.0 mg
diarrhoea 14.3% (placebo 11.5%)
constipation 9.1% (placebo 1.6%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 2.4 mg
nausea 19.5% (placebo 1.6%)
diarrhoea 14.3% (placebo 11.5%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 21.6 mg
diarrhoea 13% (placebo 11.5%)
nausea 13% (placebo 1.6%)
covid-19 11.7% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 7.2 mg
diarrhoea 21.6% (placebo 11.5%)
lipase increased 12.2% (placebo 3.3%)
nausea 12.2% (placebo 1.6%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
14 mgw
nausea 16% (placebo 5.6%)
vomiting 6.9% (placebo 2.2%)
decreased appetite 5.1% (placebo 0.6%)
NCT02906930 · Phase 3
show 38 more results
7 mg
nasopharyngitis 6.3% (placebo 3.4%)
headache 5.7% (placebo 5.1%)
diarrhoea 5.1% (placebo 2.2%)
NCT02906930 · Phase 3
3 mg
diarrhoea 8.6% (placebo 2.2%)
nausea 8% (placebo 5.6%)
nasopharyngitis 5.7% (placebo 3.4%)
NCT02906930 · Phase 3
14 mg
nausea 19.8%
diarrhoea 9.3%
vomiting 7.3%
NCT02863328 · Phase 3
14 mg
nausea 15.1%
diarrhoea 12%
nasopharyngitis 10.1%
NCT02607865 · Phase 3
7 mg
nausea 13.4%
diarrhoea 11.4%
nasopharyngitis 10.6%
NCT02607865 · Phase 3
3 mg
nasopharyngitis 11.4%
diarrhoea 9.4%
upper respiratory tract infection 7.7%
NCT02607865 · Phase 3
14 mg
nausea 19.3% (placebo 3.5%)
diarrhoea 15.1% (placebo 7.7%)
nasopharyngitis 14.4% (placebo 10.6%)
NCT02863419 · Phase 3
14 mg
nausea 19% (placebo 7.5%)
constipation 11.7% (placebo 3.7%)
vomiting 11.7% (placebo 1.2%)
NCT02827708 · Phase 3
14 mg
nausea 22.7% (placebo 7.1%)
diarrhoea 14.4% (placebo 6%)
decreased appetite 12.7% (placebo 1.1%)
NCT03021187 · Phase 3
7 mg
nausea 16.6% (placebo 7.1%)
diarrhoea 12.2% (placebo 6%)
nasopharyngitis 11.6% (placebo 14.7%)
NCT03021187 · Phase 3
3 mg
nasopharyngitis 14.7% (placebo 14.7%)
nausea 11.4% (placebo 7.1%)
diarrhoea 8.7% (placebo 6%)
NCT03021187 · Phase 3
diabetic retinopathy 19.5% (placebo 19.3%)
covid-19 15.7% (placebo 16.1%)
nausea 7.1% (placebo 1.3%)
NCT03914326 · Phase 3
covid-19 8.8%
nausea 7.6%
NCT05035082 · Phase 4 · registry result, not featured evidence
14 mg once daily
nausea 18%
diarrhoea 12.4%
covid-19 11.8%
NCT04707469 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 27.3%
vomiting 18.2%
diarrhoea 14.2%
NCT04707469 · Phase 3 · registry result, not featured evidence
25 mg once daily
nausea 27.2%
vomiting 17%
diarrhoea 12.9%
NCT04707469 · Phase 3 · registry result, not featured evidence
14 mg
diarrhoea 13.3%
nausea 12.2%
decreased appetite 9.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
7 mg
nausea 10.9%
diarrhoea 8.9%
decreased appetite 8.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
3 mg
nausea 10%
diarrhoea 8.3%
upper respiratory tract infection 7.2%
NCT04017832 · Phase 3 · registry result, not featured evidence
14 mg
decreased appetite 10.9% (placebo 0%)
diarrhoea 9.3% (placebo 1.5%)
upper respiratory tract infection 7% (placebo 4.6%)
NCT04109547 · Phase 3 · registry result, not featured evidence
7 mg
diarrhoea 9.2% (placebo 1.5%)
upper respiratory tract infection 9.2% (placebo 4.6%)
lipase increased 8.5% (placebo 0%)
NCT04109547 · Phase 3 · registry result, not featured evidence
3 mg
upper respiratory tract infection 8.5% (placebo 4.6%)
lipase increased 5.4% (placebo 0%)
nausea 4.6% (placebo 1.5%)
NCT04109547 · Phase 3 · registry result, not featured evidence
nausea 20.9%
nasopharyngitis 10.3%
headache 9.9%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 22.9%
nasopharyngitis 13.4%
diarrhoea 11.5%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 17%
diarrhoea 10%
nasopharyngitis 7%
NCT02849080 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 18.8% (placebo 28.6%)
constipation 12.5% (placebo 6.1%)
decreased appetite 12.5% (placebo 0%)
NCT03018028 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 16.3% (placebo 28.6%)
constipation 12.2% (placebo 6.1%)
nausea 10.2% (placebo 2%)
NCT03018028 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 20.4% (placebo 28.6%)
constipation 10.2% (placebo 6.1%)
periarthritis 10.2% (placebo 4.1%)
NCT03018028 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 30%
constipation 15.4%
nausea 9.2%
NCT03015220 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 29.5%
constipation 12.1%
decreased appetite 9.1%
NCT03015220 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 26%
constipation 9.2%
influenza 6.9%
NCT03015220 · Phase 3 · registry result, not featured evidence
40 mg
nausea 33.8% (placebo 1.4%)
vomiting 19.7% (placebo 4.2%)
decreased appetite 14.1% (placebo 1.4%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 35.7% (placebo 1.4%)
vomiting 22.9% (placebo 4.2%)
diarrhoea 17.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 32.9% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 15.7% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
20 mg
nausea 35.7% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 17.1% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
10 mg
nausea 33.3% (placebo 1.4%)
diarrhoea 23.2% (placebo 9.9%)
vomiting 20.3% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
5 mg
nausea 14.3% (placebo 1.4%)
headache 12.9% (placebo 5.6%)
diarrhoea 10% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
2.5 mg
nausea 12.9% (placebo 1.4%)
nasopharyngitis 8.6% (placebo 12.7%)
diarrhoea 7.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dAssessment timepoints differ: 40 weeks versus 104 weeks.
  5. ePopulation context differs: registered conditions differ.
  6. fAssessment timepoints differ: 104 weeks versus 26 weeks.
  7. gAssessment timepoints differ: 52 weeks versus 26 weeks.
  8. hAssessment timepoints differ: 56 weeks versus 26 weeks.
  9. iThe reported result categories differ.
  10. jTrial phases differ: Phase 3 versus Phase 2.
  11. kAssessment timepoints differ: 72 weeks versus 26 weeks.
  12. lTrial phases differ: Phase 4 versus Phase 3.
  13. mAssessment timepoints differ: 40 weeks versus 68 weeks.
  14. nAssessment timepoints differ: 24 weeks versus 104 weeks.
  15. oTrial phases differ: Phase 3 versus Phase 4.
  16. pAssessment timepoints differ: 72 weeks versus 52 weeks.
  17. qAssessment timepoints differ: 40 weeks versus 265 weeks.
  18. rThe assessment timepoint is not available for both results.
  19. sAssessment timepoints differ: 40 weeks versus 26 weeks.
  20. tTrial phases differ: Phase 2 versus Phase 3.
  21. uAssessment timepoints differ: 34 weeks versus 78 weeks.
  22. vPopulation comparability has not been reviewed for 43 of these studies.
  23. wPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Ozempic)

Chronic Dialysis 4.9% (n=1767) vs 5.7% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 87 Participants as posted
Acute Limb Ischemia 0.1% (n=1767) vs 0.2% (n=1766) placebo @ 234wk
event rate · % of participants
Acute limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 1 Participants as posted
Chronic Limb Ischemia Hospitalization 0.9% (n=1767) vs 1.4% (n=1766) placebo @ 234wk
event count · % of participants
Chronic limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
HbA1c Less Than 7% 72.3% (n=130) vs 24.8% (n=129) placebo @ 30wk1.0 mg weekly
responder rate · % of participants
NCT02054897 · Phase 3
show 10 more results
78.6% (n=131) vs 10.5% (n=133) placebo @ 30wk1.0 mg weekly
NCT02305381 · Phase 3
84% (n=238) vs 49.6% (n=250) Sitagliptin @ 30wk1.0 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
80.4% (n=290) vs 45.9% (n=287) Liraglutide @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
82.5% (n=120) vs 20.5% (n=127) placebo @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
78.7% (n=300) vs 52.2% (n=299) Dulaglutide @ 40wk1.0 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
74.2% (n=128) vs 24.8% (n=129) placebo @ 30wk0.5 mg weekly
Yes
NCT02054897 · Phase 3
60.6% (n=132) vs 10.5% (n=133) placebo @ 30wk0.5 mg weekly
NCT02305381 · Phase 3
74.5% (n=235) vs 49.6% (n=250) Sitagliptin @ 30wk0.5 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
68.4% (n=301) vs 52.2% (n=299) Dulaglutide @ 40wk0.5 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
76.1% (n=293) vs 50.8% (n=313) Canagliflozin @ 52wk
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than or Equal to 6.5 60% (n=130) vs 13.2% (n=129) placebo @ 30wk1.0 mg weekly
responder rate · % of participants
NCT02054897 · Phase 3
show 10 more results
61.1% (n=131) vs 4.5% (n=133) placebo @ 30wk1.0 mg weekly
NCT02305381 · Phase 3
70.6% (n=238) vs 31.6% (n=250) Sitagliptin @ 30wk1.0 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
58.5% (n=290) vs 24.8% (n=287) Liraglutide @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
60% (n=120) vs 3.9% (n=127) placebo @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
66.7% (n=300) vs 34.1% (n=299) Dulaglutide @ 40wk1.0 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
59.4% (n=128) vs 13.2% (n=129) placebo @ 30wk0.5 mg weekly
Yes
NCT02054897 · Phase 3
40.9% (n=132) vs 4.5% (n=133) placebo @ 30wk0.5 mg weekly
NCT02305381 · Phase 3
60.4% (n=235) vs 31.6% (n=250) Sitagliptin @ 30wk0.5 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
49.2% (n=301) vs 34.1% (n=299) Dulaglutide @ 40wk0.5 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
62.1% (n=293) vs 26.8% (n=313) Canagliflozin @ 52wk
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
SBP -5.61 vs -2.29 Sitagliptin mmHg @ 56wk1.0 mg weekly
absolute change · mmHg
Systolic blood pressure
NCT01930188 · Phase 3 · combination
show 1 more result
-5.07 vs -2.29 Sitagliptin mmHg @ 56wk0.5 mg weekly
Systolic blood pressure
NCT01930188 · Phase 3 · combination
DTSQs 5.91 vs 4.45 Sitagliptin score @ 56wk1.0 mg weekly
absolute change · score
NCT01930188 · Phase 3 · combination
show 4 more results
5.37 vs 3.99 Insulin Glargine score @ 30wk1.0 mg/week
NCT02128932 · Phase 3
5.28 vs 4.45 Sitagliptin score @ 56wk0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.86 vs 3.99 Insulin Glargine score @ 30wk0.5 mg/week
NCT02128932 · Phase 3
4.56 vs 2.17 Insuline Glargine U100 (Titrated) score @ 40wk
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
SF-36 Physical Component Summary 2.09 vs 1.18 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
Physical Component summary, PCS
NCT02128932 · Phase 3
show 1 more result
1.18 vs 1.18 Insulin Glargine score @ 30wk0.5 mg/week
Physical Component summary, PCS
NCT02128932 · Phase 3
SF-36 Physical Functioning 1.49 vs 0.69 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
Physical Functioning
NCT02128932 · Phase 3
show 4 more results
1.8 vs 1.4 Liraglutide score @ 30wk1.0 mg
Physical functioning
NCT03191396 · Phase 3 · registry result, not featured evidence
2 vs 2.17 Dulaglutide score @ 40wk1.0 mg
Physical functioning
NCT02648204 · Phase 3 · registry result, not featured evidence
1.64 vs 0.69 Insulin Glargine score @ 30wk0.5 mg/week
Physical Functioning
NCT02128932 · Phase 3
1.25 vs 2.17 Dulaglutide score @ 40wk0.5 mg
Physical functioning
NCT02648204 · Phase 3 · registry result, not featured evidence
SF-36 - Role Emotional 1.73 vs 0.06 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
Role-emotional
NCT02128932 · Phase 3
show 4 more results
1.2 vs 1 Liraglutide score @ 30wk1.0 mg
Role-emotional
NCT03191396 · Phase 3 · registry result, not featured evidence
1.57 vs 1.04 Dulaglutide score @ 40wk1.0 mg
Role-emotional
NCT02648204 · Phase 3 · registry result, not featured evidence
0.88 vs 0.06 Insulin Glargine score @ 30wk0.5 mg/week
Role-emotional
NCT02128932 · Phase 3
1.11 vs 1.04 Dulaglutide score @ 40wk0.5 mg
Role-emotional
NCT02648204 · Phase 3 · registry result, not featured evidence
SF-36 - Role Physical 1.97 vs 0.78 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
Role-physical
NCT02128932 · Phase 3
show 4 more results
1.4 vs 0.6 Liraglutide score @ 30wk1.0 mg
Role-physical
NCT03191396 · Phase 3 · registry result, not featured evidence
2.03 vs 1.39 Dulaglutide score @ 40wk1.0 mg
Role-physical
NCT02648204 · Phase 3 · registry result, not featured evidence
0.9 vs 0.78 Insulin Glargine score @ 30wk0.5 mg/week
Role-physical
NCT02128932 · Phase 3
0.98 vs 1.39 Dulaglutide score @ 40wk0.5 mg
Role-physical
NCT02648204 · Phase 3 · registry result, not featured evidence
SF-36 Social Functioning 1.04 vs 0.36 Insulin Glargine score @ 30wk1.0 mg/week
absolute change · score
Social functioning
NCT02128932 · Phase 3
show 4 more results
1.7 vs 0.9 Liraglutide score @ 30wk1.0 mg
Social functioning
NCT03191396 · Phase 3 · registry result, not featured evidence
0.83 vs 0.78 Dulaglutide score @ 40wk1.0 mg
Social functioning
NCT02648204 · Phase 3 · registry result, not featured evidence
1.13 vs 0.36 Insulin Glargine score @ 30wk0.5 mg/week
Social functioning
NCT02128932 · Phase 3
1.18 vs 0.78 Dulaglutide score @ 40wk0.5 mg
Social functioning
NCT02648204 · Phase 3 · registry result, not featured evidence

+ 74 further endpoints in the CSV export.

Semaglutide (Rybelsus)

HbA1c -1.5% (n=175) vs -0.3% (n=178) placebo @ 26wk14 mg
absolute change · percentage points
In-trial
NCT02906930 · Phase 3
show 11 more results
-1.3% (n=411) vs -0.9% (n=410) Empagliflozin 25 mg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-1.3% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-1.2% (n=285) vs -0.1% (n=142) placebo @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-1.1% (n=163) vs -0.2% (n=161) placebo @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-1.3% (n=181) vs -0.1% (n=184) placebo @ 26wk14 mg
In-trial
NCT03021187 · Phase 3
-1.3% (n=175) vs -0.3% (n=178) placebo @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-1.1% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1% (n=182) vs -0.1% (n=184) placebo @ 26wk7 mg
In-trial
NCT03021187 · Phase 3
-0.9% (n=175) vs -0.3% (n=178) placebo @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-0.6% (n=466) vs -0.8% (n=467) Sitagliptin @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-0.5% (n=184) vs -0.1% (n=184) placebo @ 26wk3 mg
In-trial
NCT03021187 · Phase 3
Weight -4 vs -1.4 placebo kg @ 26wk14 mg
absolute change · kg
In-trial
NCT02906930 · Phase 3
show 9 more results
-3.9 vs -3.8 Empagliflozin 25 mg kg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-3.1 vs -0.6 Sitagliptin kg @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-4.4 vs -0.6 placebo kg @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-3.5 vs -0.9 placebo kg @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-2.6 vs -1.4 placebo kg @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-2.2 vs -0.6 Sitagliptin kg @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1.5 vs -1.4 placebo kg @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-1.2 vs -0.6 Sitagliptin kg @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-2.7 vs -0.7 Sitagliptin kg @ 52wk
In-trial
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c Reduction 1% and Weight Loss 3% 50.6% (n=160) vs 10.7% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 81 Participants as posted
show 10 more results
39% (n=154) vs 7.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 60 Participants as posted
47.9% (n=332) vs 9.4% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 159 Participants as posted
45.7% (n=116) vs 9.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
36.9% (n=160) vs 10.7% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 59 Participants as posted
37.8% (n=339) vs 9.4% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 128 Participants as posted
36.8% (n=117) vs 9.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
18% (n=167) vs 10.7% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 30 Participants as posted
18.6% (n=344) vs 9.4% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
22.8% (n=114) vs 9.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
34.8% (n=230) vs 10.5% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
Time to Additional Anti-diabetic Medication 4% (n=175) vs 19.7% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 7 Participants as posted
show 36 more results
4.1% (n=411) vs 3.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 17 Participants as posted
12.7% (n=411) vs 13.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 52 Participants as posted
3.2% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 15 Participants as posted
11% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 51 Participants as posted
16.1% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 75 Participants as posted
7% (n=285) vs 8.5% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
13.7% (n=285) vs 32.4% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 39 Participants as posted
7.4% (n=163) vs 13% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 12 Participants as posted
4.4% (n=181) vs 6% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.3% (n=181) vs 40.8% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 44 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
4.6% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
6.2% (n=130) vs 12.3% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.6% (n=175) vs 19.7% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 8 Participants as posted
4.3% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 20 Participants as posted
18.5% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 86 Participants as posted
25.6% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 119 Participants as posted
4.4% (n=182) vs 6% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.7% (n=182) vs 40.8% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 45 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
12.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.3% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
9.8% (n=132) vs 12.3% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
9.1% (n=175) vs 19.7% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 16 Participants as posted
7.1% (n=466) vs 4.3% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 33 Participants as posted
29.4% (n=466) vs 23.8% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 137 Participants as posted
38.4% (n=466) vs 31.7% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 179 Participants as posted
4.9% (n=184) vs 6% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 9 Participants as posted
33.2% (n=184) vs 40.8% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 61 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
16.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
0.8% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
18.3% (n=131) vs 12.3% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
8.7% (n=253) vs 18.7% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
15% (n=100) vs 26.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
Time to Rescue Medication 1.1% (n=175) vs 15.2% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 2 Participants as posted
show 39 more results
1.9% (n=411) vs 1.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 8 Participants as posted
7.5% (n=411) vs 10.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 31 Participants as posted
1.1% (n=465) vs 2.8% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 5 Participants as posted
6.7% (n=465) vs 20.1% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 31 Participants as posted
10.1% (n=465) vs 27.6% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 47 Participants as posted
3.5% (n=285) vs 7.7% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 10 Participants as posted
7% (n=285) vs 30.3% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
4.3% (n=163) vs 9.9% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 7 Participants as posted
2.2% (n=181) vs 4.9% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 4 Participants as posted
17.1% (n=181) vs 36.4% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 31 Participants as posted
1.7% (n=361) vs 1.9% (n=359) Sitagliptin*14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
0.8% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
1.5% (n=130) vs 9.2% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
2.3% (n=175) vs 15.2% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
2.4% (n=465) vs 2.8% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 11 Participants as posted
15.7% (n=465) vs 20.1% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 73 Participants as posted
22.2% (n=465) vs 27.6% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 103 Participants as posted
1.1% (n=182) vs 4.9% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 2 Participants as posted
18.1% (n=182) vs 36.4% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 33 Participants as posted
1.7% (n=360) vs 1.9% (n=359) Sitagliptin*7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
4.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
10.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
0% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
6.1% (n=132) vs 9.2% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
7.4% (n=175) vs 15.2% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
5.4% (n=466) vs 2.8% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 25 Participants as posted
26% (n=466) vs 20.1% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 121 Participants as posted
34.3% (n=466) vs 27.6% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 160 Participants as posted
2.7% (n=184) vs 4.9% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 5 Participants as posted
29.3% (n=184) vs 36.4% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 54 Participants as posted
1.4% (n=361) vs 1.9% (n=359) Sitagliptin*3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
14.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
0% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
16.8% (n=131) vs 9.2% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
3.2% (n=253) vs 15.9% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
9% (n=100) vs 23.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 9 Participants as posted
Free Fatty Acids 0.95 vs 1.05 Empagliflozin 25 mg ratio @ 26wk14 mg
absolute change · ratio
NCT02863328 · Phase 3
show 1 more result
0.88 vs 0.97 Empagliflozin 25 mg ratio @ 52wk14 mg
NCT02863328 · Phase 3
HbA1c Less Than 7% 63.7% (n=411) vs 38.5% (n=410) Empagliflozin 25 mg @ 26wk14 mg
event count · % of participants
Week 26 · Yes
NCT02863328 · Phase 3 · converted to % from 262 Participants as posted
show 10 more results
66% (n=285) vs 13.4% (n=142) placebo @ 26wk*14 mg
Week 26 · Yes
NCT02863419 · Phase 3 · converted to % from 188 Participants as posted
55.8% (n=181) vs 6.5% (n=184) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 101 Participants as posted
72.9% (n=48) vs 12.2% (n=49) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 35 Participants as posted
80.8% (n=130) vs 69.2% (n=65) Dulaglutide @ 26wk*14 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 105 Participants as posted
40.7% (n=182) vs 6.5% (n=184) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 74 Participants as posted
67.3% (n=49) vs 12.2% (n=49) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
72.7% (n=132) vs 69.2% (n=65) Dulaglutide @ 26wk*7 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
27.2% (n=184) vs 6.5% (n=184) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 50 Participants as posted
49% (n=49) vs 12.2% (n=49) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
45% (n=131) vs 69.2% (n=65) Dulaglutide @ 26wk*3 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 59 Participants as posted
HbA1c Less Than 7% 61.8% (n=411) vs 40.2% (n=410) Empagliflozin 25 mg @ 52wk14 mg
event count · % of participants
Week 52 · Yes
NCT02863328 · Phase 3 · converted to % from 254 Participants as posted
show 10 more results
58.6% (n=285) vs 14.1% (n=142) placebo @ 52wk*14 mg
Week 52 · Yes
NCT02863419 · Phase 3 · converted to % from 167 Participants as posted
50.3% (n=181) vs 8.7% (n=184) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 91 Participants as posted
68.8% (n=48) vs 8.2% (n=49) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
69.2% (n=130) vs 49.2% (n=65) Dulaglutide @ 52wk*14 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 90 Participants as posted
36.8% (n=182) vs 8.7% (n=184) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 67 Participants as posted
59.2% (n=49) vs 8.2% (n=49) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
58.3% (n=132) vs 49.2% (n=65) Dulaglutide @ 52wk*7 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 77 Participants as posted
27.2% (n=184) vs 8.7% (n=184) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 50 Participants as posted
38.8% (n=49) vs 8.2% (n=49) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
32.8% (n=131) vs 49.2% (n=65) Dulaglutide @ 52wk*3 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
HbA1c Less Than or Equal to 6.5 45.3% (n=411) vs 16.6% (n=410) Empagliflozin 25 mg @ 26wk14 mg
event count · % of participants
Week 26 · Yes
NCT02863328 · Phase 3 · converted to % from 186 Participants as posted
show 12 more results
34.6% (n=465) vs 13.1% (n=467) Sitagliptin @ 26wk*14 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 161 Participants as posted
40.9% (n=181) vs 3.3% (n=184) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 74 Participants as posted
58.3% (n=48) vs 4.1% (n=49) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 28 Participants as posted
67.7% (n=130) vs 47.7% (n=65) Dulaglutide @ 26wk*14 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 88 Participants as posted
24.9% (n=465) vs 13.1% (n=467) Sitagliptin @ 26wk*7 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 116 Participants as posted
24.7% (n=182) vs 3.3% (n=184) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 45 Participants as posted
49% (n=49) vs 4.1% (n=49) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
50.8% (n=132) vs 47.7% (n=65) Dulaglutide @ 26wk*7 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
11.8% (n=466) vs 13.1% (n=467) Sitagliptin @ 26wk*3 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 55 Participants as posted
13% (n=184) vs 3.3% (n=184) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 24 Participants as posted
26.5% (n=49) vs 4.1% (n=49) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
30.5% (n=131) vs 47.7% (n=65) Dulaglutide @ 26wk*3 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 40 Participants as posted
HbA1c Less Than or Equal to 6.5 44.3% (n=411) vs 20.2% (n=410) Empagliflozin 25 mg @ 52wk14 mg
event count · % of participants
Week 52 · Yes
NCT02863328 · Phase 3 · converted to % from 182 Participants as posted
show 12 more results
31.4% (n=465) vs 12.6% (n=467) Sitagliptin @ 52wk*14 mg
Week 52 · Yes
NCT02607865 · Phase 3 · converted to % from 146 Participants as posted
35.9% (n=181) vs 2.2% (n=184) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 65 Participants as posted
50% (n=48) vs 2% (n=49) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
53.1% (n=130) vs 35.4% (n=65) Dulaglutide @ 52wk*14 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 69 Participants as posted
21.3% (n=465) vs 12.6% (n=467) Sitagliptin @ 52wk*7 mg
Week 52 · Yes
NCT02607865 · Phase 3 · converted to % from 99 Participants as posted
18.1% (n=182) vs 2.2% (n=184) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 33 Participants as posted
40.8% (n=49) vs 2% (n=49) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 20 Participants as posted
37.9% (n=132) vs 35.4% (n=65) Dulaglutide @ 52wk*7 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 50 Participants as posted
11.8% (n=466) vs 12.6% (n=467) Sitagliptin @ 52wk*3 mg
Week 52 · Yes
NCT02607865 · Phase 3 · converted to % from 55 Participants as posted
10.9% (n=184) vs 2.2% (n=184) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 20 Participants as posted
22.4% (n=49) vs 2% (n=49) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
16.8% (n=131) vs 35.4% (n=65) Dulaglutide @ 52wk*3 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
Weight Loss 5% 39.4% (n=411) vs 34.9% (n=410) Empagliflozin 25 mg @ 26wk14 mg
event count · % of participants
Week 26 · Yes
NCT02863328 · Phase 3 · converted to % from 162 Participants as posted
show 13 more results
28.2% (n=465) vs 9.6% (n=467) Sitagliptin @ 26wk*14 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 131 Participants as posted
42.5% (n=285) vs 7% (n=142) placebo @ 26wk*14 mg
Week 26 · Yes
NCT02863419 · Phase 3 · converted to % from 121 Participants as posted
37% (n=181) vs 2.7% (n=184) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 67 Participants as posted
33.3% (n=48) vs 6.1% (n=49) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 16 Participants as posted
30% (n=130) vs 6.2% (n=65) Dulaglutide @ 26wk*14 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 39 Participants as posted
17.4% (n=465) vs 9.6% (n=467) Sitagliptin @ 26wk*7 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 81 Participants as posted
29.1% (n=182) vs 2.7% (n=184) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 53 Participants as posted
10.2% (n=49) vs 6.1% (n=49) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
17.4% (n=132) vs 6.2% (n=65) Dulaglutide @ 26wk*7 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 23 Participants as posted
11.4% (n=466) vs 9.6% (n=467) Sitagliptin @ 26wk*3 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 53 Participants as posted
12.5% (n=184) vs 2.7% (n=184) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 23 Participants as posted
2% (n=49) vs 6.1% (n=49) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
4.6% (n=131) vs 6.2% (n=65) Dulaglutide @ 26wk*3 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
Weight Loss 5% 38% (n=411) vs 36.6% (n=410) Empagliflozin 25 mg @ 52wk14 mg
event count · % of participants
Week 52 · Yes
NCT02863328 · Phase 3 · converted to % from 156 Participants as posted
show 13 more results
31.6% (n=465) vs 10.7% (n=467) Sitagliptin @ 52wk*14 mg
Week 52 · Yes
NCT02607865 · Phase 3 · converted to % from 147 Participants as posted
43.2% (n=285) vs 11.3% (n=142) placebo @ 52wk*14 mg
Week 52 · Yes
NCT02863419 · Phase 3 · converted to % from 123 Participants as posted
37% (n=181) vs 4.9% (n=184) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 67 Participants as posted
35.4% (n=48) vs 4.1% (n=49) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
21.5% (n=130) vs 6.2% (n=65) Dulaglutide @ 52wk*14 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 28 Participants as posted
25.4% (n=465) vs 10.7% (n=467) Sitagliptin @ 52wk*7 mg
Week 52 · Yes
NCT02607865 · Phase 3 · converted to % from 118 Participants as posted
26.4% (n=182) vs 4.9% (n=184) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 48 Participants as posted
10.2% (n=49) vs 4.1% (n=49) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
15.9% (n=132) vs 6.2% (n=65) Dulaglutide @ 52wk*7 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 21 Participants as posted
14.2% (n=466) vs 10.7% (n=467) Sitagliptin @ 52wk*3 mg
Week 52 · Yes
NCT02607865 · Phase 3 · converted to % from 66 Participants as posted
16.3% (n=184) vs 4.9% (n=184) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 30 Participants as posted
2% (n=49) vs 4.1% (n=49) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
5.3% (n=131) vs 6.2% (n=65) Dulaglutide @ 52wk*3 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted

+ 83 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: July 2028 · NCT07073053 (registry estimate)

Reported efficacy

Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)

Result source: NCT04560998

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2029 · NCT07254572 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSemaglutide (Ozempic)Semaglutide (Rybelsus)
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

Semaglutide (Ozempic)
—Not reported
Semaglutide (Rybelsus)
—Not reported

Non-HDL-C, % change

Semaglutide (Ozempic)
—Not reported
Semaglutide (Rybelsus)
—Not reported

ApoB, % change

Semaglutide (Ozempic)
—Not reported
Semaglutide (Rybelsus)
—Not reported

Lp(a), % change

Semaglutide (Ozempic)
—Not reported
Semaglutide (Rybelsus)
—Not reported

3-point MACE (% with event)

Semaglutide (Ozempic)
—Not reported
Semaglutide (Rybelsus)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Semaglutide (Rybelsus): no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Semaglutide (Ozempic): 3 of 4 rows · Semaglutide (Rybelsus): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Ozempic)
Dropout rate
7.6%a
NCT04560998 · Phase 3
Discontinued due to AEs
—a
NCT04560998 · Phase 3
Serious AEs
18.7%a
NCT04560998 · Phase 3
Most frequent reported AEs
a
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Ozempic)

Max Walking Distance 1.21 vs 1.08 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.16 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
VascuQoL-6 2 vs 1 placebo score @ 52wk
absolute change · score
NCT04560998 · Phase 3
Pain-free Walking Distance 1.21 vs 1.1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.18 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
HbA1c -0.8% (n=304) vs 0.2% (n=311) placebo @ 52wk
absolute change · percentage points
NCT04560998 · Phase 3
Weight -5.2 vs -1.2 placebo kg @ 52wk
absolute change · kg
NCT04560998 · Phase 3
SBP -4 vs -1 placebo mmHg @ 52wk
absolute change · mmHg
NCT04560998 · Phase 3
Total Cholesterol 0.96 vs 1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
LDL Cholesterol 0.99 vs 1.03 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
HDL Cholesterol 1.04 vs 0.99 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
Triglyceride 0.8 vs 0.95 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
ABI 1.06 vs 1.02 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3
TBI 1.07 vs 1.04 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Semaglutide (Ozempic)'s landscape · Semaglutide (Rybelsus)'s landscape